Form 10-Q Epizyme, Inc. For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
RBC Affirms Epizyme (EPZM) at 'Outperform' as Ttazemetostat Enrollment Continues
November 9, 2015 12:43 PM ESTRBC Captial affirms Epizyme (Nasdaq: EPZM) at Outperform with a price target of $39 following Q3 results and update issued earlier.
Analyst Simos Simeonidis noted the following:
Enrollment continues in 150-patient Phase II study in NHL in Europe: On their 3Q15 earnings call this morning, management stated that plans remain on track for tazemetostat's Phase II programs. Patients are currently being enrolled in the 5-arm,... More
